Cargando…

Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents

Immune therapy improves cancer outcomes, yet many patients do not respond. This pre-clinical study investigated whether vascular disrupting agents (VDAs) could convert an immune unresponsive tumor into a responder. CDF1 mice, with 200 mm(3) C3H mammary carcinomas in the right rear foot, were intrape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horsman, Michael R., Wittenborn, Thomas R., Nielsen, Patricia S., Elming, Pernille B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370297/ https://www.ncbi.nlm.nih.gov/pubmed/32640548 http://dx.doi.org/10.3390/ijms21134778

Ejemplares similares

Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts
por: Elming, Pernille B., et al.
Publicado: (2021)

Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running
por: Lønbro, Simon, et al.
Publicado: (2019)

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments
por: Nielsen, Thomas, et al.
Publicado: (2012)

Hyperthermia: The Optimal Treatment to Overcome Radiation Resistant Hypoxia
por: Elming, Pernille B., et al.
Publicado: (2019)

Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vascular disruption
por: Hong, Sheng, et al.
Publicado: (2020)

Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model
por: Bertelsen, Lotte B, et al.
Publicado: (2014)

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions
por: Liang, Wenjie, et al.
Publicado: (2016)

Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors
por: Griffin, Robert J., et al.
Publicado: (2012)

Vascular disrupting agents in clinical development
por: Hinnen, P, et al.
Publicado: (2007)

A Combretastatin-Mediated Decrease in Neutrophil Concentration in Peripheral Blood and the Impact on the Anti-Tumor Activity of This Drug in Two Different Murine Tumor Models
por: Bohn, Anja Bille, et al.
Publicado: (2014)

Can Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?
por: Gomes, Nelson G. M., et al.
Publicado: (2015)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors
por: Bähr, Oliver, et al.
Publicado: (2017)

Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments
por: Nguyen, Linh, et al.
Publicado: (2012)

Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor
por: Fifis, Theodora, et al.
Publicado: (2013)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
por: Li, Jun-Yan, et al.
Publicado: (2021)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Disruption of Vascular Barriers in Tumors and in the Brain
por: McDannold, Nathan
Publicado: (2015)

Constrictio Cordis: Can a Thin Pericardium Restrict the Heart?
por: Elming, Marie Bayer, et al.
Publicado: (2017)

Vascular Disrupting Agent Drug Classes Differ in Effects on the Cytoskeleton
por: Kim, Sujeong, et al.
Publicado: (2012)

Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents
por: Cesca, Marta, et al.
Publicado: (2013)

Inhibition of vascular adhesion protein‐1 enhances the anti‐tumor effects of immune checkpoint inhibitors
por: Kinoshita, Tomonari, et al.
Publicado: (2021)

Tumor microenvironment: becoming sick of Myc
por: Whitfield, Jonathan R., et al.
Publicado: (2011)

Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents
por: Zhang, Dongjian, et al.
Publicado: (2018)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
por: Inno, Alessandro, et al.
Publicado: (2021)

The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy
por: Wu, Shaoxian, et al.
Publicado: (2021)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Can his research become my publication?
por: Singh, Virendra
Publicado: (2011)

Can a Peritoneal Conduit Become an Artery?
por: Davik, Petter, et al.
Publicado: (2020)

Can Computers Become Conscious and Overcome Humans?
por: Signorelli, Camilo Miguel
Publicado: (2018)

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007)

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
por: Zemek, Rachael M., et al.
Publicado: (2020)

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2016)

Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors †
por: Liu, Li, et al.
Publicado: (2021)

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
por: Lickliter, J D, et al.
Publicado: (2010)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy
por: Nasti, Tahseen H., et al.
Publicado: (2021)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j6gginka5hi7d4c1k6tsdvgadc